Healthcare provider profile · identity verified

John Clark Osborn, MD

Family Practice · MIAMI, OK · NPI 1629044334

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	564	111
Levothyroxine Sodium	Levothyroxine Sodium	421	74
Amlodipine Besylate	Amlodipine Besylate	315	68
Losartan Potassium	Losartan Potassium	300	66
Gabapentin	Gabapentin	290	64
Metoprolol Succinate	Metoprolol Succinate	283	54
Potassium Chloride	Potassium Chloride	263	49
Rosuvastatin Calcium	Rosuvastatin Calcium	239	59
Furosemide	Furosemide	233	44
Pantoprazole Sodium	Pantoprazole Sodium	221	52
Tamsulosin Hcl	Tamsulosin Hcl	192	33
Montelukast Sodium	Montelukast Sodium	188	40
Hydrochlorothiazide	Hydrochlorothiazide	186	36
Eliquis	Apixaban	179	26
Sertraline Hcl	Sertraline Hcl	176	29
Tramadol Hcl	Tramadol Hcl	165	36
Lisinopril	Lisinopril	156	38
Omeprazole	Omeprazole	154	35
Trulicity	Dulaglutide	129	17
Carvedilol	Carvedilol	120	25
Metformin Hcl	Metformin Hcl	120	25
Allopurinol	Allopurinol	111	25
Escitalopram Oxalate	Escitalopram Oxalate	107	25
Alendronate Sodium	Alendronate Sodium	104	23
Ozempic	Semaglutide	101	17
Fluticasone Propionate	Fluticasone Propionate	100	29
Clopidogrel	Clopidogrel Bisulfate	96	19
Acetaminophen-Codeine	Acetaminophen With Codeine	90	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	90	14
Duloxetine Hcl	Duloxetine Hcl	88	17
Chlorthalidone	Chlorthalidone	87	17
Donepezil Hcl	Donepezil Hcl	86	15
Spironolactone	Spironolactone	86	12
Metformin Hcl Er	Metformin Hcl	84	16
Bupropion Xl	Bupropion Hcl	77	suppressed
Alprazolam	Alprazolam	75	suppressed
Finasteride	Finasteride	74	12
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	74	13
Trazodone Hcl	Trazodone Hcl	67	15
Farxiga	Dapagliflozin Propanediol	61	suppressed
Buspirone Hcl	Buspirone Hcl	60	11
Famotidine	Famotidine	58	15
Pravastatin Sodium	Pravastatin Sodium	58	16
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	57	15
Citalopram Hbr	Citalopram Hydrobromide	55	suppressed
Celecoxib	Celecoxib	52	suppressed
Glipizide Er	Glipizide	51	suppressed
Albuterol Sulfate Hfa	Albuterol Sulfate	50	21
Pioglitazone Hcl	Pioglitazone Hcl	50	14
Pregabalin	Pregabalin	50	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	46	27
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	45	suppressed
Ezetimibe	Ezetimibe	45	12
Tizanidine Hcl	Tizanidine Hcl	44	suppressed
Simvastatin	Simvastatin	43	12
Paroxetine Hcl	Paroxetine Hcl	41	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	40	11
Isosorbide Mononitrate Er	Isosorbide Mononitrate	38	suppressed
Memantine Hcl Er	Memantine Hcl	37	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	37	suppressed
Ondansetron Hcl	Ondansetron Hcl	36	17
Invokana	Canagliflozin	35	suppressed
Mounjaro	Tirzepatide	35	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	35	26
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	34	suppressed
Linzess	Linaclotide	34	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	32	suppressed
Hydralazine Hcl	Hydralazine Hcl	29	suppressed
Jardiance	Empagliflozin	29	suppressed
Colestipol Hcl	Colestipol Hcl	26	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	26	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	26	suppressed
Propranolol Hcl	Propranolol Hcl	26	suppressed
Doxepin Hcl	Doxepin Hcl	24	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	23	suppressed
Diazepam	Diazepam	23	suppressed
Enalapril Maleate	Enalapril Maleate	23	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	23	suppressed
Sucralfate	Sucralfate	22	suppressed
Baclofen	Baclofen	21	suppressed
Lantus	Insulin Glargine,hum.Rec.Anlog	21	suppressed
Pilocarpine Hcl	Pilocarpine Hcl	21	suppressed
Prednisone	Prednisone	21	17
Warfarin Sodium	Warfarin Sodium	21	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	20	suppressed
Acyclovir	Acyclovir	19	suppressed
Mirtazapine	Mirtazapine	18	suppressed
Ropinirole Hcl	Ropinirole Hcl	18	suppressed
Ventolin Hfa	Albuterol Sulfate	18	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	17	suppressed
Glimepiride	Glimepiride	17	suppressed
Levetiracetam	Levetiracetam	17	suppressed
Lorazepam	Lorazepam	17	suppressed
Clonazepam	Clonazepam	16	suppressed
Fenofibrate	Fenofibrate	16	suppressed
Primidone	Primidone	16	suppressed
Terazosin Hcl	Terazosin Hcl	16	suppressed
Ipratropium Bromide	Ipratropium Bromide	15	suppressed
Tresiba Flextouch U-100	Insulin Degludec	15	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	14	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	14	12
Oxcarbazepine	Oxcarbazepine	14	suppressed
Xarelto	Rivaroxaban	14	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	13	11
Prazosin Hcl	Prazosin Hcl	13	suppressed
Ramipril	Ramipril	13	suppressed
Roflumilast	Roflumilast	13	suppressed
Synthroid	Levothyroxine Sodium	13	suppressed
Diclofenac Sodium	Diclofenac Sodium	12	suppressed
Lansoprazole	Lansoprazole	12	suppressed
Methocarbamol	Methocarbamol	12	suppressed
Namzaric	Memantine Hcl/Donepezil Hcl	12	suppressed
Phenobarbital	Phenobarbital	12	suppressed
Ranolazine Er	Ranolazine	12	suppressed
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	11	suppressed
Bupropion Hcl Sr	Bupropion Hcl	11	suppressed
Diltiazem 24hr Er	Diltiazem Hcl	11	suppressed
Fenofibrate	Fenofibrate,micronized	11	suppressed
Novolog Flexpen	Insulin Aspart	11	suppressed
Nystatin	Nystatin	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error